Serum ischemia modified albumin and endometrial cancer: a prospective case-control study

Objective: To investigate the importance of ischemia modified albumin (IMA) in the diagnosis and evaluation of endometrial carcinoma. Material and Methods: Serum IMA levels of patients with and without endometrial cancer were measured by the calorimetric assay technique and their absorbance units were compared. Results: A total of 128 women were included in the study; 64 of these women were endometrial cancer patients and 64 of them were in the control group. The median age for these groups were 58.5 and 56 years, respectively. There was no significant difference in terms of age, body mass index, and serum albumin levels between the groups (p > 0.05). In the endometrial cancer group, the median serum IMA level was 0.489 (0.401-0.611), while in the control group the median serum IMA level was 0.490 (0.407-0.589). There was no significant difference between these two groups (p = 0.467). In the type 1 endometrial cancer group, the median serum IMA level was 0.452 (0.401-0.590), while in the type 2 endometrial cancer group the median serum IMA level was 0.559 (0.462-0.611) A significant difference was found between types 1 and 2 endometrial cancers (p < 0.001). Conclusions: The IMA level does not appear to be an additional predictive marker of preoperative diagnosis and evaluation of endometrioid type endometrial cancer when compared to the healthy control group; on the other hand, IMA may be a marker for the detection of type 2 endometrium cancers when compared with type 1 endometrium tumors. However, further randomized controlled trials are required to make a comparison between type1 and type2 endometrial cancers.

Endometrial cancer; Endometrioid histopathology; Ischemia modified albumin (IMA).

[1] Siegel R.L., Miller K.D., Jemal A.: “Cancer Statistics, 2017”. CA Cancer J. Clin., 2017, 67, 7.

[2] Timmermans A., Opmeer B.C., Khan K.S., Bachmann L.M., Epstein E., Clark T.J., et al.: “Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis”. Obstet. Gynecol., 2010, 116, 160.

[3] Felix A.S., Weissfeld J.L., Stone R.A., Bowser R., Chivukula M., Edwards R.P., et al.: “Factors associated with Type I and Type II endometrial cancer”. Cancer Causes Control, 2010, 21, 1851.

[4] Jenabi E., Poorolajal J.: “The effect of body mass index on endometrial cancer: a meta-analysis”. Public Health, 2015, 129, 872.

[5] Setiawan V.W., Yang H.P., Pike M.C., McCann S.E., Yu H., Xiang Y.B., et al.: “Type I and II endometrial cancers: have they different risk factors?” J. Clin. Oncol., 2013, 31, 2607.

[6] Smith R.S., Kapp D.S., Chen Q., Teng N.N.: “Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy”. Int. J. Radiat. Oncol. Biol. Phys., 2000, 48, 767.

[7] Faber M.T., Frederiksen K., Jensen A., Aarslev P.B., Kjaer S.K.: “Time trends in the incidence of hysterectomy-corrected overall, type 1 and type 2 endometrial cancer in Denmark 1978-2014”. Gynecol. Oncol., 2017, 146, 359.

[8] Pecorelli S., Favalli G., Zigliani L., Odicino F.: “Cancer in women”. Int. J. Gynaecol. Obstet., 2003, 82, 369.

[9] Randall M.E., Filiaci V.L., Muss H., Spirtos N.M., Mannel R.S., Fowler J., et al.: “Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2006, 24, 36.

[10] Bagaria M., Shields E., Bakkum-Gamez J.N.: “Novel approaches to early detection of endometrial cancer”. Curr. Opin. Obstet. Gynecol., 2017, 29, 40.

[11] Zyla M.M., Wilczynski J.R., Kostrzewa M., Ksiezakowska-Lakoma K., Nowak M., Stachowiak G., et al.: “The significance of markers in the diagnosis of endometrial cancer”. Prz. Menopauzalny, 2016, 15, 176.

[12] Kemik P., Saatli B., Yildirim N., Kemik V.D., Deveci B., Terek M.C., et al.: “Diagnostic and prognostic values of preoperative serum levels of YKL-40, HE-4 and DKK-3 in endometrial cancer”. Gynecol. Oncol., 2016, 140, 64.

[13] Sbarouni E., Georgiadou P., Voudris V.: “Ischemia modified albumin changes - review and clinical implications”. Clin. Chem. Lab. Med., 2011, 49, 177.

[14] Bar-Or D., Curtis G., Rao N., Bampos N., Lau E.: “Characterization of the Co(2+) and Ni(2+) binding amino-acid residues of the N-terminus of human albumin. An insight into the mechanism of a new assay for myocardial ischemia”. Eur. J. Biochem., 2001, 268, 42.

[15] Zurawska-Plaksej E., Grzebyk E., Marciniak D., SzymanskaChabowska A., Piwowar A.: “Oxidatively modified forms of albumin in patients with risk factors of metabolic syndrome”. J. Endocrinol. Invest., 2014, 37, 819.

[16] Piwowar A., Knapik-Kordecka M., Warwas M.: “Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report”. DisMarkers, 2008, 24, 311.

[17] Collinson P.O., Rao A.C., Canepa-Anson R., Joseph S., European Society of Cardiology, American College of Cardiology: “Impact of European Society of Cardiology/American College of Cardiology guidelines on diagnostic classification of patients with suspected acute coronary syndromes”. Ann. Clin. Biochem., 2003, 40, 156.

[18] Hyspler R., Ticha A., Kaska M., Zaloudkova L., Pliskova L., Havel E., et al.: “Markers of Perioperative Bowel Complications in Colorectal Surgery Patients”. Dis. Markers, 2015, 2015, 428535.

[19] Fidan E., Mentese A., Kavgaci H., Orem A., Fidan S., Uzun A., et al.: “Increased ischemia-modified albumin levels in patients with gastric cancer”. Neoplasma, 2012, 59, 393.

[20] Ellidag H.Y., Eren E., Aydin O., Akgol E., Yalcinkaya S., Sezer C., et al.: “Ischemia modified albumin levels and oxidative stress in patients with bladder cancer”. Asian Pac. J. Cancer Prev., 2013, 14, 2759.

[21] Miric D.J., Kisic B.M., Filipovic-Danic S., Grbic R., Dragojevic I., Miric M.B., et al.: “Xanthine Oxidase Activity in Type 2 Diabetes Mellitus Patients with and without Diabetic Peripheral Neuropathy”. J. Diabetes Res., 2016, 2016, 4370490.

[22] Cakir E., Ozbek M., Ozkaya E., Colak N., Cakal E., Sayki M., et al.: “Oxidative stress markers are not valuable markers in lean and early age of polycystic ovary syndrome patients”. J. Endocrinol. Invest., 2011, 34, e178-82.

[23] Yarci Gursoy A., Caglar G.S., Demirtas S.: “Ischemia modified albumin in perinatology”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2017, 210, 182.

[24] Kilic M.O., Guldogan C.E., Balamir I., Tez M.: “Ischemia-modified albumin as a predictor of the severity of acute appendicitis”. Am. J. Emerg. Med., 2017, 35, 92.

[25] Ram Chander S., Varikasuvu S.R., Anil Kumar P., Rupanagudi A.: “Ischemia modified albumin concentrations in patients with rheumatoid arthritis”. Int. J. Rheum. Dis., 2017, 20, 2152.

[26] Yin M., Liu X., Chen X., Li C., Qin W., Han H., et al.: “Ischemiamodified albumin is a predictor of short-term mortality in patients with severe sepsis”. J. Crit. Care, 2017, 37, 7.

[27] Duarte M.M., Rocha J.B., Moresco R.N., Duarte T., Da Cruz I.B., Loro V.L., et al.: “Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia”. Clin. Biochem., 2009, 42, 666.

[28] Trabert B., Eldridge R.C., Pfeiffer R.M., Shiels M.S., Kemp T.J., Guillemette C., et al.: “Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial”. Int. J. Cancer, 2017, 140, 600.

[29] Mantovani A., Allavena P., Sica A., Balkwill F.: “Cancer-related inflammation”. Nature, 2008, 454, 436.

[30] Bredholt G., Mannelqvist M., Stefansson I.M., Birkeland E., Bo T.H., Oyan A.M., et al.: “Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses”. Oncotarget, 2015, 6, 39676.

[31] Chen Y.L., Huang C.Y., Chien T.Y., Huang S.H., Wu C.J., Ho C.M.: “Value of pre-operative serum CA125 level for prediction of prognosis in patients with endometrial cancer”. Aust. N. Z. J. Obstet. Gynaecol., 2011, 51, 397.

[32] Ellidag H.Y., Bulbuller N., Eren E., Abusoglu S., Akgol E., Cetiner M., et al.: “Ischemia-modified albumin: could it be a new oxidative stress biomarker for colorectal carcinoma?” Gut. Liver, 2013, 7, 675.

[33] Stachowicz-Stencel T., Synakiewicz A., Owczarzak A., Sliwinska A., Lysiak-Szydlowska W., Balcerska A.: “Parameters of antioxidant barrier in different histopathologic types of pediatric cancers”. Contemp. Oncol. (Pozn.), 2012, 16, 165.

[34] Da Silveira R.A., Hermes C.L,. Almeida T.C., Bochi G.V., De Bona K.S., Moretto M.B., et al.: “Ischemia-modified albumin and inflammatory biomarkers in patients with prostate cancer”. Clin. Lab., 2014, 60, 1703.

[35] Satoh M., Kotani K., Gugliucci A., Horie H., Caccavello R., Takeuchi M.: “Correlation of ischemia-modified albumin with SOFA and APACHE II scores in preoperative patients with colorectal cancer”. ScientificWorldJournal, 2014, 2014, 959075.